Skip to content

Comparative Analgesic Effect After Total Knee Arthroplasty Between Intraosseous and Peri-articular Injection

Comparative Analgesic Effect After Total Knee Arthroplasty Between Intraosseous Multimodal Analgesic Agent Injection Versus Periarticular Injection - A Randomized Control Trial

Status
Enrolling by invitation
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06800846
Enrollment
90
Registered
2025-01-30
Start date
2024-09-01
Completion date
2025-06-30
Last updated
2025-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain Postoperative, Total Knee Anthroplasty, Functional Outcomes

Keywords

peri-articular injection, intraosseous injection, multimodal analgesia cocktail, TKA, pain postoperative, functional outcomes

Brief summary

The goal of this RCT is to compare analgesic effect after total knee arthroplasty between intraosseous multimodal analgesic agent injection versus periarticular injection. The main question\[s\] it aims to answer are: Does Intraosseous multimodal analgesic cocktail injection have more post-operative analgesic effect than Peri-articular injection in patients who have done TKA (P)? Participants will randomized to intraosseous injection group or peri-articular injection group and will record the 100-mm VAS pain scores for 2 weeks after TKA. Researchers will compare to peri-articular injection group to see pain and functional outcomes after TKA.

Detailed description

Intra-operatively, you will be randomly assigned to receive intraosseous multimodal analgesic agent injection or peri-articular multimodal analgesic agent injection along with other standard medications. In the intraosseous injection group: Participants received combinations of 0.5% bupivacaine 100 mg + 0.1% adrenaline 0.6 mg + Morphine 5mg + Ketorolac 30 mg (totally 22 ml) which divided by 12 ml inject into intramedullary canal before bone plug impaction to close the canal and 10 ml inject into metaphysis of tibia before cementation and implantation. In the peri-articualr injection group: Participants received combinations of the same drug and mix with normal saline solution for totally 75 ml which divided by 25 ml inject into medial gutter and 25 ml inject into lateral gutter before cementation and implantation. And the last 25 ml of multimodal analgesic drugs were injected into quadriceps.

Interventions

Participants received combinations of 0.5% bupivacaine 100 mg + 0.1% adrenaline 0.6 mg + Morphine 5mg + Ketorolac 30 mg (totally 22 ml) which divided by 12 ml inject into intramedullary canal before bone plug impaction to close the canal and 10 ml inject into metaphysis of tibia before cementation and implantation

Participants received combinations of 0.5% bupivacaine 100 mg + 0.1% adrenaline 0.6 mg + Morphine 5mg + Ketorolac 30 mg and mix with normal saline solution for totally 75 ml which divided by 25 ml inject into medial gutter and 25 ml inject into lateral gutter before cementation and implantation. And the last 25 ml of multimodal analgesic drugs were injected into quadriceps.

Sponsors

Thammasat University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* 50 - 80 yrs of age ASA classification: 1-3 Unilateral TKA

Exclusion criteria

* Secondary OA knee Previous knee surgery Can't undertaken spinal block and adductor canal block Renal insuf. (Crcl \< 30 ml/min) History of convulsive disorder Abnormal liver function BMI \> 35 Kg/M2 Allergy to study drugs History of coronary disease Hb \< 10 (g/dl) Can't understand 100mm-VAS assessment Refuse to recruit in the study, or refuse follow up Using opioid in 5 days before surgery Unstable vital sign History current VTE Using anti-platelet or anti-coagulation medicine Severe deformity

Design outcomes

Primary

MeasureTime frameDescription
pain scoresat 4, 6 hours and every 6 hours after surgery for 2 days, then daily for 2 weeks after surgery.Visual analog scale at rest and motion (0-100 points, 0 mean best, 100 mean worst)

Secondary

MeasureTime frameDescription
number of vomit eventsat first 48 hours before discharge and after discharge for 2 weeks after surgerynumber of vomit events
Number of other Events of Morphine side effect2 weeks after surgeryItching, rash, constipation, difficult urination, respiratory, etc.
ROMbefore surgery and 24, 48hours and 2 weeks after surgeryROM (degree)
Timed up and go testat 48 hours and 2 weeks after surgerystart with standing and then walk for 3 meters, then turn back to seat for 3 meters, then sit (report in seconds)
Morphine consumption2 weeksMorphine consumption in hospital 48 hours before discharge and MST as home medication for 2 weeks (MME)
Time to walkup to 48 hourshours after surgery of patients at first start walking to the toilet
Operative timeup to 2 hoursduration from start incision to wound closure in TKA procedure (minutes)
Number of other complication2 weeksclinical VTE, wound and skin complication, superficial and deep infection
Length of stays in hospitalup to 72 hoursNumber of hours the patient stays for surgery

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026